{"id":"NCT01257230","sponsor":"Boehringer Ingelheim","briefTitle":"Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma","officialTitle":"A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety Over 48 Weeks of Orally Inhaled Tiotropium Bromide (2.5 and 5 µg Once Daily ) Delivered by the Respimat® Inhaler in Adolescents (12 to 17 Years Old) With Moderate Persistent Asthma.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2010-12-09","resultsPosted":"2014-08-08","lastUpdate":"2014-09-05"},"enrollment":398,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"tiotropium Respimat low dose","otherNames":[]},{"type":"DRUG","name":"placebo Respimat","otherNames":[]},{"type":"DRUG","name":"tiotropium Respimat high dose","otherNames":[]}],"arms":[{"label":"placebo","type":"PLACEBO_COMPARATOR"},{"label":"tiotropium low dose","type":"EXPERIMENTAL"},{"label":"tiotropium high dose","type":"EXPERIMENTAL"}],"summary":"The aim of the study is to evaluate efficacy and safety of a 48-week treatment with two doses of tiotropium bromide compared to placebo in adolescent patients with moderate persistent asthma. Efficacy and safety will be assessed by measuring lung function parameters and evaluating the effects on asthma exacerbations, on Quality of life, on health care resource utilisation an on the number of adverse events.","primaryOutcome":{"measure":"FEV1 peak0-3 Change From Baseline","timeFrame":"Baseline and 24 weeks","effectByArm":[{"arm":"Placebo Respimat","deltaMin":0.373,"sd":0.037},{"arm":"Tio R2.5","deltaMin":0.507,"sd":0.04},{"arm":"Tio R5","deltaMin":0.547,"sd":0.038}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0085"},{"comp":"OG000 vs OG002","p":"0.0005"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":66,"countries":["United States","Chile","Germany","Hungary","Italy","Latvia","Mexico","Russia","Slovakia","South Korea","Spain","Ukraine"]},"refs":{"pmids":["36472162","32180164","31319851","26960245"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":138},"commonTop":["Asthma","Nasopharyngitis","Respiratory tract infection viral","Peak expiratory flow rate decreased","Viral infection"]}}